ONTX - Onconova Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Onconova Therapeutics, Inc.

375 Pheasant Run
Newtown, PA 18940
United States
267-759-3680
http://www.onconova.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees25

Key Executives

NameTitlePayExercisedYear Born
Admiral Steven M. FruchtmanCEO, Pres & Director805.72kN/A1951
Dr. E. Premkumar ReddyFounder, Lead Scientific Advisor & Director30kN/A1944
Dr. Manoj ManiarSr. VP of Product Devel.544.84kN/A1963
Dr. Ramesh KumarAdvisor732.68kN/A1956
Mr. Mark Patrick GuerinChief Financial OfficerN/AN/A1969
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Corporate Governance

Onconova Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.